and overall survival benefits in transplant-ineligible patients with newly diagnosed multiple myeloma. Emerging data also ...

"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

The first trial I wanted to discuss is the phase 2 GRIFFIN trial [NCT02874742]. This looked at patients with ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). A final decision is expected in the coming months.

Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...